America’s biopharmaceutical research companies are developing 444 new medicines to prevent and treat neurological disorders, according to a new report released by the Pharmaceutical Research and Manufacturers of America (PhRMA).
More than 600 neurological disorders, ranging from well-known disorders such as epilepsy, multiple sclerosis and Parkinson’s disease, to more obscure conditions such as Duchenne muscular dystrophy and Friedreich's ataxia, strike millions of Americans each year.
These potential medicines, all in human clinical trials or under review by FDA include:
82 medicines for Alzheimer’s disease, which afflicts more than 5 million Americans
82 for pain; 100 million US adults experience chronic pain
62 for brain tumors; nearly 70,000 Americans are diagnosed each year with a primary brain tumor
38 for multiple sclerosis, which afflicts an estimated 500,000 Americans
25 for headache, including migraine, a condition that affects more than 37 million Americans
28 for epilepsy and seizures, which impacts more than 3 million Americans
27 for Parkinson’s disease, which affects as many as 1 million Americans
Of the 444 medicines in development, many represent novel, exciting scientific approaches to target diseases, such as a gene therapy to restore neuronal function in Alzheimer’s patients, targeted therapies for neuromuscular disorders and gene therapy to restore cells damaged in Parkinson’s patients.